High CDCA2 expression was associated with more advanced pathological features in clear-cell renal cell carcinoma (ccRCC), colorectal cancer (CRC), prostate cancer, oral squamous cell carcinoma (OSCC), lung adenocarcinoma, breast cancer, melanoma, and pancreatic ductal adenocarcinoma (Uchida et al., 2013; Wang et al., 2016; Shi et al., 2017; Feng et al., 2019; Zhang et al., 2020; Li et al., 2020; Chen et al., 2020; Jin et al., 2020). The gene discussed is CDCA2; the disease is nonpapillary renal cell carcinoma.